Cycling, Air Pollution and Health (CAPaH)
Introduction: Cycling is currently promoted at the municipal, provincial and national level as a form of active transportation that increases physical activity while at the same time reducing traffic congestion, traffic-related air pollution and greenhouse gas emissions. While at a population level the health benefits of exercise via cycling are estimated to substantially exceed any health impacts related to air pollution exposure and injuries from traffic accidents , cyclists are known to experience elevated exposures to traffic-related air pollutants. Combined with exposure to elevated concentrations of air pollutants, cyclists also are subject to substantially increased inhaled doses due to their level of exertion and consequently increased inhalation rate. Therefore, given that cyclists experience exposures to relatively high concentrations of traffic-related air pollutants and that their inhalation of these pollutants is increased, it is important to evaluate the potential health impacts of this scenario. Research on the potential health impacts related to exercise (cycling) and urban air pollution exposure can help inform public communication strategies related to air quality and its health impacts. In addition, as our previous work suggests substantial variability in air pollution exposures to cyclists that is related to the route type and the levels of traffic along cycling routes, there is potential for transportation planners to promote increased cycling by enhancing infrastructure while at the same time developing routes that also minimize exposure to air pollution. The cyclist population is also interested in information regarding the air pollution exposures and potential health impacts related to cycling.
The objective of this study is to investigate the relationship between traffic-related air pollution exposure, and respiratory and cardiovascular health impacts in commuting cyclists. Specifically, the investigators propose to:
- determine commuting cyclists' exposure to traffic-related air pollutants (PM 2.5, PM10, ultrafine particulate, black carbon) while cycling along two different bicycle routes in the city of Vancouver;
- estimate the pollutant dose received by each cyclist, and relate this to the health effects observed; and
- determine if there is a change in lung function, endothelial function, and C-reactive protein level related to the level of air pollution exposure and dose
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6T 1Z3
- Air Pollution Exposure Lab, Vancouver General Hospital through the School of Population and Public Health, University of British Columbia
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age 19- 39
- male or female
- able to bicycle comfortably on city streets for 1 hour
Exclusion Criteria:
- Smokers of any substance (smoking more than 1x every 2 weeks)
- Must be of height to safely ride a test bike (<5'2", >6'5" )
- Diagnosed asthma or active allergy (hav fever) symptoms
- Irregular menstrual cycle, pregnant, breastfeeding, non-monocyclic contraceptive medication or device
- Taking medication for heart or lung condition
- Answers yes to any questions on physical activity readiness questionnaire (PAR-Q)
- requires pain medication daily
- visual or hearing impairment that prevents safe cycling on streets with motor vehicles
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Normal cycling
Cycling on a residential and downtown route (crossover design)
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Change in endothelial function, as measured by peripheral arterial tonometry (EndoPAT) score of reactive hyperemia index (RHI)
Zeitfenster: Baseline (1 hour pre-expousre) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
Baseline (1 hour pre-expousre) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Change in lung function (using spirometry to assess lung function values)
Zeitfenster: Baseline (1 hour pre-exposure) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
Baseline (1 hour pre-exposure) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Change in blood levels of C-reactive protein (a marker of systemic inflammation)
Zeitfenster: Baseline (1 hour pre-exposure) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
Baseline (1 hour pre-exposure) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
|
Change in blood levels of Interleukin-6 (a marker of systemic inflammation)
Zeitfenster: Baseline (1 hour pre-exposure) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
Baseline (1 hour pre-exposure) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
|
Change in blood levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG)(a marker of oxidative stress)
Zeitfenster: Baseline (1 hour pre-exposure) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
Baseline (1 hour pre-exposure) and 1 hour post- exposure (plus or minus 30 minutes) to a bicycle ride in an urban environment outdoors
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Michael Brauer, ScD, The University of British Columbia
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- H10-00902
- H1008-111481/001/XSB (Andere Kennung: UBC CREB)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Endotheliale Dysfunktion
-
Centre Hospitalier Régional Metz-ThionvilleAbgeschlossenStripping Automated Endothelial Keratoplasty von Descemet
-
Aarhus University HospitalZurückgezogenEndotheldystrophie | Sekundäre bullöse Keratopathie | Hintere lamelläre Keratoplastik | Stripping Endothelial Keratoplasty nach DescemetDänemark
-
Oslo University HospitalRekrutierungDescemet Stripping Automatisierte endotheliale Keratoplastik (DSAEK) | Descemet Membrane Endothelial Keratoplasty (DMEK)Norwegen
-
Roberta BallardMallinckrodt; ONYAbgeschlossenBronchopulmonale Dysplasie | Atemnotsyndrom der Frühgeborenen (Surfactant Dysfunction)Vereinigte Staaten
Klinische Studien zur Cycling on a residential route
-
Maharishi Markendeswar University (Deemed to be...Abgeschlossen
-
Meyer Children's Hospital IRCCSAktiv, nicht rekrutierendChronische NierenerkrankungenItalien
-
Onconova Therapeutics, Inc.AbgeschlossenSicherheit von ON 01910.Na und Irinotecan oder ON 01910.Na und Oxaliplatin bei Patienten mit HepatomFortgeschrittener solider Tumor | HepatomVereinigte Staaten
-
elbion AGBeendet
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)UnbekanntKastrationsresistentes Prostatakarzinom | Metastasierendes Prostatakarzinom | Stadium IVB Prostatakrebs AJCC v8 | Kastrationsspiegel von Testosteron | Prostatakarzinom im Knochen metastasiertVereinigte Staaten
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Aktiv, nicht rekrutierendMetastasierendes Adenokarzinom des Pankreas | Bauchspeicheldrüsenkrebs im Stadium IV AJCC v6 und v7 | Darmkrebs Stadium IV AJCC v7 | Darmkrebs im Stadium IVA AJCC v7 | Darmkrebs im Stadium IVB AJCC v7 | Metastasierendes Adenokarzinom des gastroösophagealen Überganges | Metastasierendes kolorektales... und andere BedingungenVereinigte Staaten
-
Thomas Jefferson UniversityAbbVieRekrutierungMyelodysplastisches Syndrom | Wiederkehrendes myelodysplastisches Syndrom | Refraktäres myelodysplastisches SyndromVereinigte Staaten
-
National Cancer Institute (NCI)AbgeschlossenKeimzelltumor der Eierstöcke im Stadium IV | Rezidivierender Keimzelltumor der Eierstöcke | Hodenkrebs im Stadium III | Rezidivierender bösartiger Hodenkeimzelltumor | Rezidivierendes extragonadales Seminom | Rezidivierender maligner extragonadaler Keimzelltumor | Rezidivierender maligner extragonadaler... und andere BedingungenVereinigte Staaten
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityBeendetPrimäre Myelofibrose | Anämie | Rezidivierendes Hodgkin-Lymphom | Refraktäres Hodgkin-Lymphom | Anatomischer Brustkrebs im Stadium IV AJCC v8 | Wiederkehrende akute myeloische Leukämie | Wiederkehrendes myelodysplastisches Syndrom | Refraktäre akute myeloische Leukämie | Refraktäre chronische myelomonozytäre... und andere BedingungenVereinigte Staaten